Elisabeth Dhondt1, Peter Vanlangenhove2, Karen Geboes3, Lisbeth Vandenabeele4, Lien Van Cauwenberghe2, Luc Defreyne2. 1. Department of Vascular and Interventional Radiology, Ghent University Hospital, C. Heymanslaan 10, 9000, Ghent, Belgium. elisabeth.dhondt@uzgent.be. 2. Department of Vascular and Interventional Radiology, Ghent University Hospital, C. Heymanslaan 10, 9000, Ghent, Belgium. 3. Department of Gastroenterology, Ghent University Hospital, C. Heymanslaan 10, 9000, Ghent, Belgium. 4. Department of Gastroenterology, Saint-Joseph Clinic Bornem and Willebroek, Bornem, Belgium.
Abstract
OBJECTIVE: To investigate whether covered stents show a higher efficacy than uncovered stents in percutaneous treatment of malignant hilar biliary obstruction. METHODS:Patients with obstructive jaundice caused by an unresectable hilar malignancy were included after failedendoscopic intervention in a prospective randomized trial comparing expanded polytetrafluoroethylene and fluorinated ethylene propylene (ePTFE-FEP)-covered nitinol stents with uncovered nitinol stents. Exclusion criteria were as follows: primary tumors existing more than 3 months, a biliodigestive anastomosis, previous stenting, and a Karnofsky score of less than 50. Safety, clinical success, and adjuvant chemotherapy were compared as well as occlusion rate, patency, and survival. RESULTS:A total of 120 patients were included. One patient was post hoc excluded. Fourteen patients who died within 7 days and one patient without patency data were excluded from patency analysis. Serious adverse events (p = 0.4), 30-day mortality (p = 0.5), and clinical success (p = 0.8) were equivalent for both stent groups. Twenty-one out of 61 (34%) patients in the covered and 24/58 (41%) in the uncovered stent groups received adjuvant chemotherapy (p = 0.5). Occlusion rate was 54% (27/50) in the covered stent group and 57% (31/54) in the uncovered stent group (p = 0.8). Median patency was 229 days (95% CI 113-345) for covered stents and 130 days (95% CI 75-185) for uncovered stents (p = 0.1). Median survival in patients with covered stents was 79 days (95% CI 52-106) and with uncovered stents 92 days (95% CI 60-124) (p = 0.3). CONCLUSION: In malignant hilar biliary obstruction, there is no evidence that ePTFE-FEP-covered stents are superior to uncovered stents in terms of safety, clinical success, adjuvant chemotherapy, patency, or survival. KEY POINTS: • Percutaneous palliation of hilar biliary obstruction is feasible with both uncovered and covered stents. • Clinical success in terms of bilirubin decrease and adjuvant chemotherapy is achievable with both stents. • Thirty-day mortality is considerable when stenting is also offered to patients with a low performance status.
RCT Entities:
OBJECTIVE: To investigate whether covered stents show a higher efficacy than uncovered stents in percutaneous treatment of malignant hilar biliary obstruction. METHODS:Patients with obstructive jaundice caused by an unresectable hilar malignancy were included after failed endoscopic intervention in a prospective randomized trial comparing expanded polytetrafluoroethylene and fluorinated ethylene propylene (ePTFE-FEP)-covered nitinol stents with uncovered nitinol stents. Exclusion criteria were as follows: primary tumors existing more than 3 months, a biliodigestive anastomosis, previous stenting, and a Karnofsky score of less than 50. Safety, clinical success, and adjuvant chemotherapy were compared as well as occlusion rate, patency, and survival. RESULTS: A total of 120 patients were included. One patient was post hoc excluded. Fourteen patients who died within 7 days and one patient without patency data were excluded from patency analysis. Serious adverse events (p = 0.4), 30-day mortality (p = 0.5), and clinical success (p = 0.8) were equivalent for both stent groups. Twenty-one out of 61 (34%) patients in the covered and 24/58 (41%) in the uncovered stent groups received adjuvant chemotherapy (p = 0.5). Occlusion rate was 54% (27/50) in the covered stent group and 57% (31/54) in the uncovered stent group (p = 0.8). Median patency was 229 days (95% CI 113-345) for covered stents and 130 days (95% CI 75-185) for uncovered stents (p = 0.1). Median survival in patients with covered stents was 79 days (95% CI 52-106) and with uncovered stents 92 days (95% CI 60-124) (p = 0.3). CONCLUSION: In malignant hilar biliary obstruction, there is no evidence that ePTFE-FEP-covered stents are superior to uncovered stents in terms of safety, clinical success, adjuvant chemotherapy, patency, or survival. KEY POINTS: • Percutaneous palliation of hilar biliary obstruction is feasible with both uncovered and covered stents. • Clinical success in terms of bilirubin decrease and adjuvant chemotherapy is achievable with both stents. • Thirty-day mortality is considerable when stenting is also offered to patients with a low performance status.
Authors: Raymond H Thornton; Robert Ulrich; Meier Hsu; Chaya Moskowitz; Diane Reidy-Lagunes; Anne M Covey; Lynn A Brody; Piera M Robson; Constantinos T Sofocleous; Stephen B Solomon; George I Getrajdman; Karen T Brown Journal: J Vasc Interv Radiol Date: 2011-11-23 Impact factor: 3.464
Authors: Jennifer L Levy; Deepak Sudheendra; Mandeep Dagli; Jeffrey I Mondschein; S William Stavropoulos; Richard D Shlansky-Goldberg; Scott O Trerotola; Ursina Teitelbaum; Rosemarie Mick; Michael C Soulen Journal: Abdom Radiol (NY) Date: 2016-02
Authors: H Isayama; Y Komatsu; T Tsujino; N Sasahira; K Hirano; N Toda; Y Nakai; N Yamamoto; M Tada; H Yoshida; Y Shiratori; T Kawabe; M Omata Journal: Gut Date: 2004-05 Impact factor: 23.059
Authors: Maria Schoder; Plinio Rossi; Renon Uflacker; Mario Bezzi; Alfred Stadler; Martin A Funovics; Manfred Cejna; Johannes Lammer Journal: Radiology Date: 2002-10 Impact factor: 11.105
Authors: Cyril Chivot; Clara Yzet; Roger Bouzerar; Franck Brazier; Sami Hakim; Jean Philippe Le Mouel; Eric Nguyen-Khac; Richard Delcenserie; Thierry Yzet Journal: Surg Endosc Date: 2020-07-24 Impact factor: 4.584
Authors: Marco Das; Christiaan van der Leij; Marcus Katoh; Daniel Benten; Babs M F Hendriks; Adam Hatzidakis Journal: Cardiovasc Intervent Radiol Date: 2021-07-29 Impact factor: 2.740